Skip to main content
OpenTrials
Completed

NCT Number: NCT07331025

Ultrasound Detection of Early Facial Muscle Changes in FSHD: Thickness and Echo Intensity Findings

Facioscapulohumeral muscular dystrophy (FSHD) is characterized by early and significant involvement of facial muscles; however, objective imaging data focusing on facial muscles are limited. Facial ultrasound can serve as a sensitive imaging biomarker and outcome measure by capturing regional structural changes in facial muscles associated with disease progression in FSHD patients.

The aim of this study is to compare facial muscle thickness and echo density between FSHD patients and healthy controls using ultrasound and to examine the relationships between ultrasound findings and clinical parameters.

This study will include 20 patients with genetically confirmed FSHD1 diagnosis and 19 age- and sex-matched healthy controls. Using musculoskeletal ultrasound, bilateral evaluation of selected facial muscles (Orbicularis oculi, orbicularis oris, zygomaticus major, and buccinator) will be performed by two different researchers, and muscle thickness and muscle echo density will be recorded. Inter-rater reliability will be assessed using intraclass correlation coefficients. Group comparisons and correlation analyses will be performed with clinical scores, symptom duration, and D4Z4 repeat size.

The results will evaluate whether ultrasound can reliably detect structural changes in FSHD that cannot be captured by traditional clinical assessments, and if significant, will suggest that ultrasound can serve as a sensitive imaging biomarker for early and region-specific facial muscle involvement in FSHD.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Facioscapulohumeral Muscular Dystrophy Congenital, Hereditary, and Neonatal Diseases and Abnormalities Facioscapulohumeral Muscular Dystrophy 1 Genetic Diseases, Inborn Muscular Diseases Muscular Disorders, Atrophic Muscular Dystrophies Muscular Dystrophy, Facioscapulohumeral Musculoskeletal Diseases Nervous System Diseases Neuromuscular Disease Neuromuscular Diseases

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Koç University Hospital

Istanbul, 34010, Turkey (Türkiye)

About this study

Facioscapulohumeral muscular dystrophy (FSHD) is a hereditary neuromuscular disorder characterized by progressive muscle weakness, showing early and significant involvement of facial muscles. Despite their diagnostic and functional importance, facial muscles are often underrepresented in imaging-based assessments of disease involvement. This observational, cross-sectional study was designed to compare structural changes in selected facial muscles of individuals with genetically confirmed FSHD with healthy controls using musculoskeletal ultrasound. The study focuses on the quantitative assessment of muscle thickness and the qualitative assessment of muscle echo density as indicators of atrophy and fat infiltration. Bilateral ultrasound examinations will be performed on facial muscles, including the orbicularis oculi, orbicularis oris, zygomaticus major, and buccinator muscles, which play a role in facial expression and oral function. Imaging findings will be evaluated in relation to clinical features to investigate whether facial muscle ultrasound can provide region-specific information not captured by global disease severity scores. This study aims to characterize facial muscle involvement using a non-invasive and accessible imaging method, contribute to the understanding of early and subclinical facial muscle changes in FSHD, and support the potential role of ultrasound as an imaging biomarker in neuromuscular disorders.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18-55 years
  • Genetically confirmed facioscapulohumeral muscular dystrophy type 1 (FSHD1) (patient group)
  • Age- and sex-matched healthy volunteers without neuromuscular disease (control group)
  • Ability to provide written informed consent

Exclusion criteria

  • Presence of other neurological or neuromuscular disorders
  • History of facial palsy or facial trauma
  • Botulinum toxin injection to facial muscles within the last 6 months
  • Inability to cooperate with ultrasound assessment

Treatment and study plan

Primary outcomes

  1. Facial muscle thickness measured by ultrasound

    Time frame: Baseline

    Bilateral thickness (in millimeters) of the orbicularis oculi, orbicularis oris (superficial and deep layers), zygomaticus major, and buccinator muscles measured using B-mode musculoskeletal ultrasound at standardized anatomical reference points.

  2. Facial muscle echo intensity

    Time frame: Baseline

    Muscle echogenicity of the same facial muscles assessed bilaterally using the Modified Heckmatt Scale (grades 1-4) to evaluate structural changes and fatty infiltration on B-mode ultrasound images.

Secondary outcomes

  1. Inter-rater reliability of facial muscle ultrasound measurements

    Time frame: Baseline

    Agreement between independent raters assessed using intraclass correlation coefficients for facial muscle thickness and echo intensity measurements.

Sponsors and collaborators

Lead sponsor

Koç University

Other

Registry information

Official study title

Ultrasound Detection of Early Facial Muscle Changes in FSHD: Thickness and Echo Intensity Findings - A Cross-Sectional Comparison With Healthy Adults

Acronym: FACIAL-FSHD

Important dates

Study start
2023
Primary completion
2023
Study completion
2024
First posted
Jan 9, 2026
Registry last updated
Jan 9, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.